We, Mahatma Gandhi Cancer Hospital & Research Institute, have organized the “The FIRST AP state conference on NEUROENDOCRINE TUMORS” on 8th-April-2018 in Visakhapatnam. During this event, the best minds of this region related to NETs discussed on the related topics!
Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.
The World Health Organization (WHO) classification scheme places neuroendocrine tumors into three main categories, which emphasize the tumor grade rather than the anatomical origin:
Grand Inauguration of “The FIRST AP State Conference on Neuroendocrine Tumors” by Dr CV Rao, Vice Chancellor of NTRUHS, Dr CH. Lakshmana Rao of APMC and Dr Jakir Ali of ANMPI graced the occasion, along with Conference Organising Chairman Dr Murali Krishna Voonna and organizing Secretary Dr Raghava Kashyap.
Professor Mukta Ramadwar, from Tata Memorial Hospital, Mumbai, explained about NETs, their classification and grades of NETs.
Dr. Archi Agarwal, from Tata Memorial Hospital, Mumbai, explained about ever increasing role of Positron Emission Tomography with 68Ga-DOTATOC and 18F-FDG in staging and characterizing #NETs and how it prognosticates and guides treatment decisions.
Dr. B Surendra Kumar, Seven Hills Hospital, Visakhapatnam explained about ‘Cross-sectional imaging with CT & MRI in the detection of NET’.
Dr. A. Chalapati Rao explained about ‘Endoscopy guided diagnosis & it’s role in Tissue Acquisition in NETs’.
Dr. Rinkesh Bansal from Fortis Hospital, Gurgaon explained his personal experience on treatment of NETs.
Dr. Raja Pramanik, Assistant Professor, Medical Oncology from All India Institute of Medical Sciences, Delhi explained about the treatment options for patients with metastatic NETs.
Dr. Sundeep Lakhtakia from Asian Institute of Gastroenterology explained about ‘The exciting field of non-surgical therapeutic procedures’.
Symptoms of NETs are the most troubling for the patients and can sometimes be life-threatening.
‘It is not the end of the road for patients with metastatic NETs’.
Dr. K Raghava Kashyap, Nuclear Medicine Specialist from Mahatma Gandhi Cancer Hospital explained about the ‘Role of 177 Lutetium Based Peptide Receptor Radionuclide Therapy (PRRT) for patients with metastatic NETs’ with metastatic NETs and how they can be benefited from the treatment.
Panel Discussion on ‘NETs’ towards the end of the conference on Neuroendocrine Tumors.